Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lumacaftor/Ivacaftor on Exercise Tolerance in CF
NCT02875366Phase 4Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Sep 2016; status: completed.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02875366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875366.